ASTRAZEN6,843.00

AstraZeneca Pharma India Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSANOFICONRPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCMcap ₹17,108 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,295.51,716.32,275.62,432.1
Other Income34.840.628.526.5
Total Income1,330.31,756.92,304.12,458.5
Expenses
+ Cost of Materials Consumed129.0287.19.50.0
+ Purchases of Stock-in-Trade499.31,008.81,859.41,746.5
+ Changes in Inventories-33.8-332.9-488.4-214.1
+ Employee Benefit Expense241.5257.4264.4279.1
+ Finance Costs1.21.54.55.7
+ Depreciation & Amortisation14.940.028.617.2
+ Other Expenses275.1241.9368.6390.8
Total Expenses1,127.21,503.82,046.62,225.2
EBITDA184.4254.0262.0229.9
EBIT169.5214.0233.5212.6
Profit
PBT before Exceptional Items203.1253.2257.5233.4
+ Exceptional Items16.4-96.8-5.3-5.1
Pretax Income219.5156.4252.2228.3
+ Current Tax53.660.559.448.2
+ Deferred Tax4.5-19.95.310.4
Tax Expense58.040.664.758.6
Net Income161.5115.7187.5169.6
+ Net Income — Continuing Ops161.5115.7187.5169.6
+ Other Comprehensive Income1.0-1.2-4.4-5.4
Total Comprehensive Income162.5114.6183.1164.3
Per Share
Basic EPS64.6046.3075.0167.85
Diluted EPS64.6046.300.0034.73
Other Comprehensive Income — detail
+ Other Comprehensive Income-1.2-4.4-5.4
+ Items NOT to be Reclassified to P&L1.3-1.6-5.9-7.2
+ Tax on Items NOT to be Reclassified-0.4-1.5-1.8
+ Tax on Items NOT to be Reclassified — alt tag0.3
Per Share — as-filed variants
Basic EPS — Continuing Operations64.6046.3075.0167.85
Diluted EPS — Continuing Operations64.6046.300.0034.73
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit701.0753.3895.0899.7
Gross Margin %54.1143.8939.3336.99
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)203.1253.2257.5233.4
− Exceptional Items (reconciliation)16.4-96.8-5.3-5.1
Net Income Adj (tax-effected)149.4187.4191.4173.4
EPS Adj59.7774.9676.5769.37
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital5.05.05.05.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.